Since its launch in 2014, Roivant has formed more than 20 Vants. These companies are reinventing the discovery, development, and commercialization of new medicines in areas as diverse as oncology, neurology, immunology, and rare diseases. To date, they have advanced the development of more than 40 drug candidates.
As an industry pioneer, Roivant empowers a global team of innovators within and beyond the biopharmaceutical industry to tackle the most pressing challenges in healthcare today. Their work requires daily exploration and analysis of scientific literature to support strategic decisions and help them assess the market opportunity for new healthcare products.
With previous tools unable to scale or provide the support they needed, the Roivant team looked to find a better solution, which is where Papers Enterprise came in.